U.S.-based PleoPharma announced yesterday that the FDA has granted it a fast-track designation for PP-01, a new ...

The global remote patient monitoring market, valued at US$24.39 billion in 2023, is forecasted to grow at a robust CAGR of 12 ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new USC research.

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Sen. Scott Wiener (D-San Francisco) has introduced two bills in the State Senate that could lower prescription drug prices ...

It earns 3% cash back at specific merchants and 2% back on everything else — but only if you use the card with Apple Pay. It's not a game-changer, but the card does offer some intriguing ...

Rocketing demand, legal disputes, and the future of weight loss were all spurred by a new class of anti-obesity medications.